Senores Pharmaceuticals Ltd.

1,405.10-48.0 (-3.30%)

17 Jul, 12:00 AM

Income Statement

Abridged

Understanding Income Statement

Senores Pharmaceuticals Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	14.17	35.34	214.52	398.25	632.63
Cost of Operating Revenue	8.74	14.54	121.58	212.82	282.91
Gross Profit	5.43	20.79	92.94	185.43	349.72
Gross Margin	38.3	58.8	43.3	46.6	55.3
Total Operating Expenses	12.92	24.29	182.92	325.39	495.56
Operating Profit	1.25	11.05	31.61	72.86	137.07
Operating Margin	8.8	31.3	14.7	18.3	21.7
Financing Income/(Expense) - Net	-0.57	1.28	-8.38	-10.99	-25.03
Profit before Taxes	1.14	12.44	24.94	70.57	159.10
Income Taxes	0.15	4.00	-7.76	12.23	37.57
Profit after Tax	0.99	8.43	31.46	58.56	115.37
PAT Margin	7.0	23.9	14.7	14.7	18.2
EPS - Basic - ex Extraordinary Items	0.30	2.54	9.46	16.10	26.39
EPS - Diluted - ex Extraordinary Items	0.30	2.54	9.46	16.10	26.39
EBIT	1.25	11.05	31.61	72.86	137.07
EBITDA	1.95	12.83	41.63	89.70	168.32
EBITDA Margin	13.8	36.3	19.4	22.5	26.6

Balance Sheet

Abridged

Understanding Balance Sheet

Senores Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	PRESS
Total Current Assets	27	51	251	722	812
Long-Term Investments	16	17	19	1	39
Property Plant & Equipment - Net	6	15	179	252	363
Total Non-Current Assets	32	80	371	504	791
Total Assets	59	131	622	1,227	1,604
Total Current Liabilities	10	52	248	241	424
Long Term Debt	13	31	141	171	208
Total Non-Current Liabilities	13	34	143	174	215
Total Liabilities	23	86	390	415	639
Total Shareholders' Equity	37	45	204	786	934
Minority Interest	-	-	27	26	31
Total Equity	37	45	232	812	965
Total Liabilities & Equity	59	131	622	1,227	1,604

Cash Flow

Abridged

Understanding Cash Flow Statement

Senores Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	1.86	13.47	32.95	77.62	196.32
Working Capital - Increase/(Decrease)	-12.62	-16.35	-66.69	-136.74	-145.30
Net CF from Operating Activities	-10.76	-2.88	-33.74	-59.12	51.02
Capital Expenditures - Net	10.68	47.28	51.83	157.52	264.55
Net CF from Investing Activities	-24.63	-48.33	-54.69	-436.64	-134.56
Stock - Issuance/(Retirement) - Net	4.94	1.07	36.99	15.55	-
Debt - LT & ST - Issuance/(Retirement) - Total	10.41	46.59	59.84	121.74	2.00
Net Cash Flow from Financing Activities	36.97	48.09	95.48	593.49	23.70
Free Cash Flow to Equity	-11.03	-3.57	-25.73	-94.90	-211.53
Free Operating CF net dividend	-21.45	-50.15	-85.57	-216.64	-213.71
Free Operating CF	-21.45	-50.15	-85.57	-216.64	-213.71

Business Segment Analysis

FY End:

Mar 25

Senores Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 157.52 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 398.25 Cr

Assets

Pharmaceuticals (100.0%)₹ 1,226.86 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 72.86 Cr

Regional Segment Analysis

FY End:

Mar 25

Senores Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Outside India (73.7%)₹ 293.33 CrWithin India (26.3%)₹ 104.92 Cr

Historical Segment Analysis

Track how Senores Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2025 Mar 31

Pharmaceuticals	158

Frequently Asked Questions

What is the revenue of Senores Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Senores Pharmaceuticals Ltd. is ₹ 632.63 Cr, reflecting a 1-year growth of 58.85% and a 3-year CAGR of 161.60%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Senores Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Senores Pharmaceuticals Ltd. is ₹ 115.37 Cr, with a 3-year earnings CAGR of 118.35%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Senores Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Senores Pharmaceuticals Ltd. is approximately ₹ 137.07 Cr (based on an operating margin of 21.67%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Senores Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Senores Pharmaceuticals Ltd. is 26.39. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Senores Pharmaceuticals Ltd.?

The debt-to-equity ratio of Senores Pharmaceuticals Ltd. stands at 0.37. The interest coverage ratio is 5.48x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Senores Pharmaceuticals Ltd.?

The estimated book value per share of Senores Pharmaceuticals Ltd. is 202.72 (derived from a P/B ratio of 6.93 and market price of ₹ 1,405.10), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Senores Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Senores Pharmaceuticals Ltd. is ₹ 51.02 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Senores Pharmaceuticals Ltd. report consolidated or standalone financials?

Senores Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.